medigraphic.com

2012, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (2)

Effect of two crystalloid fluids schemes on glucose serum levels in patients with severe preeclampsia

Vázquez-Rodríguez JG, Becerril-Serrano A

Language: Spanish
References: 23
Page: 183-188
PDF size: 77.63 Kb.


ABSTRACT

Background: treatment of severe preeclampsia (SP) includes administration of crystalloid solutions to expand plasma circulating volume. Our objective was to compare the effects of two schemes of crystalloid solutions on glycemia in patients with SP.
Methods: cross-sectional study with two groups of patients: group A (123 patients) received a 10 % glucose solution and group B (146 patients) received Ringer lactate solution. We compared glycemia, endogenous creatinine clearance (ECrCl), frequency of urinary tract infection (UTI) and length of hospital stay. Student t-test and Pearson correlation coefficient were used.
Results: final glycemia of group A was higher than group B (168.27 ± 70.85 adversus 94.20 ± 26.63, p = 0.009). No differences were shown in ECrCl (group A 99.26 ± 30.67 adversus group B, p = 0.14) or in UTI [group A 21.95 % (27 cases) adversus group B 18.48 % (27 cases) (p = 0.43)]. Length of hospital stay was different (group A 2.2 ± 1.79 adversus group B 2.67 ± 1.78 days, p = 0.03).
Conclusions: patients receiving a 10 % glucose solution presented significant hyperglycemia but not in the group receiving Ringer lactate solution.


REFERENCES

  1. Lyell DJ, Lambert-Messerlian GM, Giudice LC. Prenatal screening, epidemiology, diagnosis, and management of preeclampsia. Clin Lab Med 2003;23(2):413-442.

  2. Bourjeily G, Miller M. Obstetrics disorders in the ICU. Clin Chest Med 2009;30(4):89-102.

  3. Bolte AC, van Geijn HP, Dekker GA. Management and monitoring of severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001;96(1):8-20.

  4. Vázquez RJG. Hipertensión arterial por preeclampsiaeclampsia. México; Editorial Prado; 2007. p. 164.

  5. Instituto Mexicano del Seguro Social. Norma técnica médica para la prevención y manejo de la preeclampsia-eclampsia. México: IMSS, Dirección de Prestaciones Médicas: 2005. p. 20.

  6. Secretaría de Salud. Prevención, diagnóstico y manejo de la preeclampsia-eclampsia. Lineamiento técnico. México: Secretaría de Salud, Centro Nacional de Equidad de Género y Salud Reproductiva; 2007. p. 34. Disponible en http://www. salud.gob.mx/unidades/cdi/documentos/PREECLAMPSIA _ECLAMPSIA_lin-2007.pdf

  7. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth 2009;9:8-22. Disponible en http://www.ncbi. nlm.nih.gov/pmc/articles/PMC2654858/?tool=pmcentrez

  8. Bagshaw SM, Egi M, George C, Bellomo R; Australia New Zealand Intensive Care Society Database Management Committee. Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 2009;37 (2):463-470.

  9. Tutina M, Chrit-Crain M, Polk HC Jr. Diabetes and hyperglycemia: strict glycemic control. Crit Care Med 2006:34 (Supl 9):S291-S300.

  10. Manzanares W, Aramendi I. Hiperglucemia de estrés y su control con insulina en el paciente crítico: evidencia actual. Medicina Intensiva 2009;10:1-8. Disponible en http://www. elsevier.es/sites/default/files/elsevier/eop/S0210-5691 (09)00112-0.pdf

  11. Fahy BG, Sheehy AM, Coursin DB. Glucose control in the intensive care unit. Crit Care Med 2009;37(5):1769-1775.

  12. Solomon CG, Seely EW. Hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hyper tension 2001;37(2):232-239. Disponible en http://hyper. ahajournals.org/content/37/2/232.long

  13. Wahl WL, Taddonio, Maggio T, Arbabi S, Hemmila MR. Mean glucose values predict trauma patient mortality. J Trauma 2008;65(1):42-47.

  14. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003;290 (15):2041-2047. Disponible en http://jama.ama-assn.org/ content/290/15/2041.long

  15. Chávez-Pérez JP, Sánchez-Velázquez LD. Glucemia como un determinante de morbimortalidad en el paciente en estado crítico. Rev Asoc Mex Med Crit Ter Int 2009; 23(1):25-30. Disponible en http://www.medigraphic.com/ pdfs/medcri/ti-2009/ti091e.pdf

  16. Van Den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest Ch, Schetz M, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003:31(2):359-366.

  17. Egi M, Bellomo R. Stachowski E, French CJ, Hart GK, Hegarty C, Bailey M. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Critic Care Med 2008;36(8):2249-2255.

  18. Foley MR, Strong T Jr, Garite T. Obstetric intensive care manual. Philadelphia: Saunders WB; 2005. p. 188.

  19. Zeeman GG. Obstetric critical care: a blueprint for improved outcomes. Crit Care Med 2006;34(Supl 9):S208- S214.

  20. Light IJ, Kreenan WJ, Sutherland JM. Maternal intravenous glucose administration as a cause of hypoglycemia in the infant of the diabetic mother. Am J Obstet Gynecol 1972;113(3):345-350.

  21. Tobin JD, Roux JF, Soeldner JS. Human fetal insulin response after acute maternal glucose administration during labor. Pediatrics 1969;44(5):668-671.

  22. Robillard JE, Sessions C, Kennedy RL, Smith FG Jr. Metabolic effects of constant hypertonic glucose infusion in welloxygenated fetuses. Am J Obstet Gynecol 1978;130(2): 199-203.

  23. Philipson EH, Kalhan SC, Riha MM, Pimentel R. Effects of maternal glucose infusion on fetal acid-base status in human pregnancy. Am J Obstet Gynecol 1987;157(4 Pte 1): 866-873.




2020     |     www.medigraphic.com